![](/img/cover-not-exists.png)
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System
L. Paz-Ares, J. G. Del Muro, E. Grande, S. DíazVolume:
35
Year:
2010
Language:
english
Pages:
1
DOI:
10.1111/j.1365-2710.2009.01135.x
File:
PDF, 170 KB
english, 2010